The AHA and several safety-net providers argue that an upcoming mandatory rebate pilot violates administrative law, imposes millions in costs, and threatens patient care in vulnerable communities.

Hospital groups raise issues with 340B rebate pilot program citing cash flow, administrative costs, and unclear rebate denials risks.

Recent data released by the Health Resources and Services Administration show that drug purchases made under the 340B Drug Pricing Program totaled $81.4 billion in 2024.

Healthcare policy changes may increase uncompensated care, stressing hospitals and the 340B program, crucial for subsidizing low-income patient care. The 340B rebate model, starting in 2026, could ...

Some hospitals are buying life-saving medications for pennies, then charging low-income patients, including many with disabilities, hundreds of dollars for these drugs. They do it every day under a ...

The 340B drug pricing program is complicated. A clinic leader and a hospital said that’s making it easy for there to be misunderstandings about if the savings are being passed onto the patient.

Hospitals are suing to block a Trump administration pilot that will allow drugmakers to issue post-sale rebates instead of upfront discounts on medications in the 340B drug discount program, arguing ...

340B is a tremendous federal program that ought to be fixed — by the federal government. A state initiative would make things worse. Credit: Getty Images. When something isn't working, we look to our ...

It’s no surprise that chronic illness and affordability challenges can cause job loss, slow up wage gain and prevent work entirely. All Americans don’t share this burden equally, though. Minorities — ...

An AHA blog examines new data released by the Health Resources and Services Administration on the growth of the 340B Drug ...